Sonoma Pharmaceuticals Inc Dossier - Source-backed chat

Sonoma Pharmaceuticals Inc

SNOANASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.18

Intrinsic Value $1.19median of 2 methodsbased on filings through 31 Mar 2026

Market Price $1.25Price as of 1 Oct 2026

Near fair valueIntrinsic value is 5% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $6M

Enterprise Value $3.8M

Shares Outstanding 4.8M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Sonoma Pharmaceuticals is showing strong top-line momentum, particularly in the U.S. OTC and wound care markets, driven by its stabilized hypochlorous acid (HOCl) technology. However, the company remains structurally unprofitable with a tight cash runway, requiring frequent dilutive capital raises. While the commercial expansion is promising, listing compliance risks and high volatility make it a speculative hold.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.4520%

OTC expansion fails to generate sufficient margins to offset rising SG&A expenses. Tightening cash reserves force highly dilutive financing, and failure to maintain Nasdaq listing requirements leads to delisting to OTC markets.

Base CaseCentral scenario

$1.2050%

Sonoma continues to grow revenues at a 15-20% annual rate, gradually narrowing its EBITDA losses. The company remains dependent on occasional capital raises, keeping the stock range-bound due to dilution and Nasdaq compliance overhang.

Bull CaseUpside scenario

$2.0030%

Accelerated adoption of HOCl-based products in major retail channels (CVS, Walmart) and partnerships (Medline) drives Sonoma to profitability ahead of the estimated 2028 timeline, leading to significant multiple expansion.

Scenarios reflect our research view at the research date.

Key Investment Merits

Strong revenue growth of 37% YoY in FY2026, led by a 117% surge in U.S. sales.
Established partnerships with major distributors and retailers like Medline, CVS, and Walmart.
Proprietary, clinically-proven Microcyn® HOCl technology platform with global regulatory clearances.

Key Investment Risks

Persistent net losses ($3.18 million in FY2026) and negative cash flows from operations.
High risk of equity dilution, as evidenced by the $4 million public offering in April 2026.
Nasdaq listing compliance risk if the stock price or market value falls below minimum thresholds.

Thesis Invalidation Triggers

Loss of key distribution partnerships with Medline or major retail accounts.
Delisting from the Nasdaq Capital Market.
Severe margin contraction below 35% due to inflation or supply chain disruptions in Mexico manufacturing.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.